-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Amt7A8BRc0pGwykRCJBE9lbdeAhajfsRP4RtUJlEsvk1cBjUFN3STpQN7IwyvhPm ZJceCdpcan8r15ICP0RJXA== 0000950144-96-004026.txt : 19960708 0000950144-96-004026.hdr.sgml : 19960708 ACCESSION NUMBER: 0000950144-96-004026 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19960705 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHYCOR INC/TN CENTRAL INDEX KEY: 0000881400 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 621344801 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 033-98528 FILM NUMBER: 96591576 BUSINESS ADDRESS: STREET 1: 30 BURTON HILLS BLVD STREET 2: STE 400 CITY: NASHVILLE STATE: TN ZIP: 37215 BUSINESS PHONE: 6156659066 MAIL ADDRESS: STREET 1: 30 BURTON HILLS BLVD STREET 2: STE 400 CITY: NASHVILLE STATE: TN ZIP: 37215 424B5 1 PHYCOR, INC. 424B5 1 REGISTRATION NO. 33-98528 FILED PURSUANT TO RULE 424(b)(5) SUPPLEMENT TO PROSPECTUS, DATED OCTOBER 24, 1995 PHYCOR, INC. 3,000,000 SHARES COMMON STOCK The Prospectus, dated May 3, 1996 (the "Prospectus"), to which this Supplement, dated July 3, 1996, is attached (the "Supplement"), relates to the resale by the holders thereof of up to 3,000,000 shares of the Company's Common Stock, no par value per share ("Common Stock"), issued upon the conversion of subordinated convertible notes issued or to be issued by the Company without registration under the Securities Act of 1933, as amended (the "Act") in connection with the acquisition of the assets of (i) single and multi-specialty medical clinics, (ii) the assets of individual physician practices and (iii) the assets of related businesses, including, but not limited to, management services organizations, consulting firms and other physician management companies. In addition, this Prospectus also relates to the resale by certain holders of Common Stock issued upon the exercise of options granted by the Company prior to the adoption by the Company of its stock incentive plans and warrants issued as consideration for (i) consulting or other services provided or to be provided to the Company and (ii) the execution of a management or service agreement with the Company or an affiliate. Pursuant to an Asset Purchase Agreement, effective as of October 1, 1994 (the "Purchase Agreement"), PhyCor of Boulder, Inc., a Tennessee corporation and wholly-owned subsidiary of the Company ("PhyCor-Boulder"), acquired substantially all of the operating assets of Boulder Medical Center, P.C., a Colorado professional corporation (the "Clinic"). In connection with this transaction, the Company issued a 7.0% Subordinated Convertible Note (the "Note") to the Clinic. Subsequently, the Clinic partially converted the Note into unregistered shares of Common Stock, as more fully described herein. Terms defined in the Prospectus have the same meaning in this Supplement unless the context otherwise requires. All share numbers used herein give effect to a three-for-two stock split of the Common Stock effected on June 14, 1996 in the form of a 50% stock dividend. THIS SUPPLEMENT INCORPORATES DOCUMENTS BY REFERENCE WHICH ARE NOT PRESENTED HEREIN OR DELIVERED HEREWITH. THESE DOCUMENTS ARE AVAILABLE UPON WRITTEN OR ORAL REQUEST, AT NO CHARGE, FROM THE COMPANY. REQUESTS SHOULD BE DIRECTED TO PHYCOR, INC., 30 BURTON HILLS BOULEVARD, SUITE 400, NASHVILLE, TENNESSEE 37215, ATTENTION: N. CAROLYN FOREHAND, VICE PRESIDENT AND GENERAL COUNSEL. The date of this Supplement is July 5, 1996. 2 Selling Shareholders Each selling shareholder (each a "Physician") is licensed to practice medicine pursuant to the laws of the State of Colorado and practices medicine through the Clinic. The Company, through PhyCor-Boulder, acquired substantially all of the assets of the Clinic pursuant to the Purchase Agreement. In connection therewith, the Company issued the Note to the Clinic. On January 4, 1996, the Clinic partially converted the Purchase Note, in accordance with its terms, into an aggregate of 180,762 shares of Common Stock. The Clinic resold 135,918 of such shares pursuant to a Prospectus Supplement dated January 4, 1996. The remaining shares were distributed on a pro rata basis to certain of the Clinic's existing shareholders. On April 1, 1996, the Clinic partially converted the Purchase Note, in accordance with its terms, into an aggregate of 31,551 shares of Common Stock. The Clinic resold 17,241 of such shares pursuant to a Prospectus Supplement dated April 9, 1996. The remaining Shares were distributed on a pro rata basis to certain of the Clinic's existing shareholders. On July 1, 1996, the Clinic partially converted the Purchase Note, in accordance with its terms, into an aggregate of 11,424 shares of Common Stock. The Clinic resold 2,475 of such shares pursuant to a Prospectus Supplement dated July 1, 1996. The remaining 8,949 shares (the "Resale Shares") were distributed to the Physicians on a pro rata basis based upon their respective ownership interests in the Clinic. The Resale Shares may be resold by a Physician through a registered broker-dealer in accordance with the terms of the Prospectus. The aggregate number of Resale Shares that may be resold by each Physician is indicated on Schedule A hereto. Plan of Offering This Supplement relates to the reoffering, from time to time, of the Resale Shares through a registered broker-dealer. The resale of the Resale Shares will be effected through a registered broker-dealer in private or block transactions in the over-the-counter market (including The Nasdaq Stock Market's National Market) or otherwise at fixed prices which may be changed, at market prices prevailing at the time of the sale, at prices related to such prevailing market price, or at negotiated prices. The broker-dealer may effect such transactions by selling the Resale Shares to or through other broker-dealers, and such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the purchasers of the Resale Shares for whom such broker-dealers may act as agent or to whom they may sell as principal, or both (which compensation as to a particular broker-dealer might be in excess of customary commissions). As a result of the reoffering of the Resale Shares pursuant to the Prospectus, as supplemented hereby, the Company and the respective broker-dealer may be deemed to be "underwriters" within the meaning of Section 2(11) of the Act, and any commissions received by (or discounts allowed to) them and any profit on the resale of the Resale Shares as principal may be deemed to be underwriting discounts and commissions. 2 3 SCHEDULE A Steven Hong 7,824 shares 150 Greenrock Drive Boulder, CO 80304 Steven Weiner 1,125 shares 5479 Ptarmigan Cir. Boulder, CO 80301 -----END PRIVACY-ENHANCED MESSAGE-----